drugset / Trial / NCT03031912
African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola
Phase 2
Completed
251 enrolled
Canadian Immunization Research Network
Centre Muraz · collabCoalition for Epidemic Preparedness Innovations · collabDalhousie University · collabInstitute for Health Research - Epidemiological Surveillance and Training (IRESSEF) · collabInternational Development Research Centre, Canada · collabMerck Sharp & Dohme LLC · collabUniversity of Ottawa · collabUniversité de Montréal · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
This is a randomized, placebo-controlled, multi-site, double-blind trial of V920 (rVSVΔG-ZEBOV-GP) Ebola Virus vaccine candidate in subjects with HIV infection to be conducted in conformance with Good Clinical Practices. The study will take place at 2 Canadian sites (Centre Hospitalier de l'Université de Montréal and Ottawa General Hospital) and 2 African sites (Centre MURAZ, Burkina Faso and Centre Hospitalier National Aristide Le Dantec, Dakar, Senegal). The Duration of Study: 365 days for each participant not including screening.
Timeline
- Start
- 2017-08-01
- Primary completion
- 2023-03-03
- Completion
- 2023-03-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | V920 | Vaccine | 2e+07 unknown | — |